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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not is
liraglutide effective for weight loss in adults who are overweight or obese compared to placebo.
STUDY DESIGN: Review of three double-blind, randomized controlled trials published after
2010.
DATA SOURCES: All three English language, double-blind, randomized controlled trials were
found using PubMed. All three RCT’s were published in peer reviewed journals.
OUTCOMES MEASURED: The outcome measured was loss of 7% or more of body weight
from baseline in the study by Sun et al., and loss of greater than 10% of body weight from
baseline in the studies by Pi-Sunyer et al. and Davies et al.
RESULTS: The RCT performed by Davies et al. showed 25.2% of subjects in the liraglutide
3.0mg group lost more than 10% of baseline body weight compared to 6.7% in the placebo
group (p< 0.001). The RCT performed by Sun et al. showed 54% of subjects in the liraglutide
1.8mg group lost 7% of baseline body weight compared to 4% in the placebo group (p< 0.001).
The RCT performed by Pi-Sunyer et al. showed 33.1% of subjects in the liraglutide 3.0mg
group lost more than 10% of baseline body weight compared to 10.6% in the placebo group
(p< 0.001).
CONCLUSIONS: The results of all three RCT’s included in this review indicate that the use of
liraglutide is effective for weight loss in adults. These studies demonstrated that dosages of
liraglutide 1.8 mg and 3.0 mg worked in reducing body weight from baseline when compared to
placebo. Future studies should include lower dosages of liraglutide to assess the efficacy they
have in weight loss.
KEY WORDS: Liraglutide, weight loss
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INTRODUCTION
Obesity is considered a national epidemic and more than 70% of American adults are
overweight or obese.1 It is well known that Americans weigh more now than they did in the last
decade. In 2016, more than 1.9 billion adults (39%), 18 years and older, were overweight, of
these over 650 (13%) million were obese.2 Being overweight or obese can be caused by high
calorie intake, poor diet, lack of physical activity, genetics, underlying medical conditions, or
certain medications. A high BMI can be an indicator of high body fatness. If the BMI is 25.0 to <
30, it falls within the overweight range and if the BMI is 30.0 or higher it falls within the obese
range. In 2012, 11 million visits, or an annual visit rate of 49 visits per 1000 persons, to
physician offices for obesity were made by adults aged 20 and over.3 Weight loss can prevent or
at least slow down major risk factors of obesity that include adverse cardiac events, diabetes,
dyslipidemia, sleep-disordered breathing, diastolic dysfunction, joint problems and others, and,
by doing this, possibly decrease morbidity and mortality in the long term.4 All these
complications mentioned are a major concern for patients and physician assistants. Physician
assistants in the primary and hospital setting will encounter patients that are suffering from the
complications of being overweight or obese and; thus, will have to come forth with a plan to help
their patients effectively lose weight. Even a modest weight loss of 5 to 10% of the total body
weight can produce health benefits, such as improvements in blood pressure, blood cholesterol,
and blood sugar.
Obesity not only cost people their health but it comes at a monetary cost as well. It costs
the global economy about $2 trillion annually or 2.8% of global GDP.5 Research suggests that
the percentage of U.S. health spending on treatment of obesity related illnesses in adults climbed
29% between 2001 and 2015.5 Individuals with obesity have 42% higher healthcare costs than
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people of normal weight and each 1-point increase in BMI leads to a 4% increase in medical
costs and a 7% increase in pharmaceutical costs.5 The pharmaceutical cost of a one-month
supply of liraglutide at the target dose of 3.0 mg per day is approximately $1194.6 That cost is
an out of pocket cost without insurance coverage being applied.
Currently, there are a few options available for weight loss, such as healthy lifestyle
changes including heart healthy eating and physical activity, bariatric surgeries including Rouxen-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding, and FDA approved
medications including orlistat, lorcaserin, phentermine-topiramate, and liraglutide.7 With
almost half of American adults making an effort to lose weight, the treatment options mentioned
play an effective role in helping them achieve their goals.8
Liraglutide may be used as an effective agent in helping adults obtain weight loss. It is a
glucagon-like peptide 1 (GLP-1) analog, with 97% homology to human GLP-1 and a therapeutic
potential for both obesity and type 2 diabetes owing to its dual benefits on body weight and
glycemic control.9 GLP-1 analogs like liraglutide not only suppress glucagon but they induce
satiety which leads to reducing appetite and food intake and; thus, subsequent weight reduction.
OBJECTIVE
The objective of this systematic review is to determine whether or not is liraglutide
effective for weight loss in adults who are overweight or obese compared to placebo.
METHODS
The criteria used for the selection of the three studies included adults. The three studies in
this review were found by searching the PubMed database. The keywords used for this search
were “liraglutide” and “weight loss”. The three articles were chosen for this review because they
proved relevant to the clinical question and the outcomes were measured by Patient-Oriented
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Evidence that Matters. The inclusion criteria included randomized controlled trial, clinical trial,
studies published after 2010, humans, and English language. Exclusion criteria included studies
published earlier than 2010. The three studies that were selected were double-blind, randomized
controlled trials comparing liraglutide to placebo. All three studies were published in the English
language in peer-reviewed journals from 2013 to 2015. The statistics used included RBI, ABI,
NNT, and p-values.
The intervention evaluated in the Sun et al. study was once-daily subcutaneous injections
of liraglutide 1.8 mg compared to placebo. The interventions evaluated in Pi-Sunyer et al. and
Davies et al. studies were once-daily subcutaneous injections of liraglutide 3.0 mg compared to
placebo.
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Table 1. Demographics and Characteristics of Included Studies
Study

Type

#Pts
846

Age
(yrs)
 18

Inclusion
criteria
Adults aged 18
with a stable
body weight,
BMI of 27
kg/m2,
diagnosed with
type 2 diabetes
treated with diet
and exercise
alone or in
combination
with 1-3 oral
hypoglycemic
agents

Davies
(2015)

Double
blind
RCT

Sun
(2013)

Double
blind
RCT

68

40-70

Men and
women, age 4070 years, BMI
of 27-40 kg/m2
with prediabetes
& required to
have a stable
weight ( 5%
reported
change) in the
previous 3
months

PiSunyer
(2015)

Double
blind
RCT

3731

 18

Adults aged
18, stable body
weight, BMI of
at least 30 kg/m2
or a BMI of at
least 27 kg/m2 if
they had treated
or untreated
dyslipidemia or
hypertension

Exclusion criteria

W/D

Treatment w/ any
218
antidiabetic drug
other than
metformin w/in last
3 mos., obesity
from other
endocrinologic d/o,
surgical treatment
for obesity, current
participation in wt.
loss program, diet
attempts using
herbal supplements,
history of MEN
type 2 or medullary
thyroid carcinoma,
cancer, suicidal
ideation, behavior
or attempt
DM2, use of meds
17
that can affect carb
metabolism or
promote wt. loss,
gallstones, hx of
pancreatitis,
medullary
carcinoma, family
hx of medullary
carcinoma or MEN
type 2, and known
cardiac, liver, or
kidney disease
DM1 or DM2, meds 895
that cause clinically
significant weight
gain/loss, previous
bariatric surgery, hx
of pancreatitis, hx
of psychiatric d/o,
hx of MEN type 2
or familial
medullary thyroid
carcinoma

Interventions
Received
liraglutide
subcutaneously
once daily.
Starting dose=
0.6mg, tittered
by 0.6 mg
weekly to dose
of 3.0mg

Received
liraglutide
subcutaneously
once daily.
Starting dose=
0.6mg, tittered
by 0.6mg
weekly to max
dose of 1.8mg

Received
liraglutide
3.0mg
subcutaneously
once daily
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OUTCOMES MEASURED
The outcome measured in all three studies was percentage of body weight lost from
baseline. In the Sun et al. study the outcome measured was loss of greater than or equal to 7% of
body weight from baseline. The subjects were weighed at baseline and then at the completion of
the 14 week treatment.10 In the Pi-Sunyer et al. and Davies et al. studies the outcome measured
was loss of greater than 10% of body weight from baseline. In the Pi-Sunyer et al. study subjects
were evaluated every 2 weeks until week 8, then every 4 weeks until week 44, and then again at
weeks 50, 56, 58, 60, 64, 68, and 70.11 In the Davies et al. study body weight was measured at
every visit to week 68.9 The bodyweight in all three studies was measured in kilograms.
RESULTS
In all three studies subjects were randomly chosen to receive treatment to lose
bodyweight. The Davies et al. study focused on overweight or obese adults aged 18 years and
older over a 56 week trial. Eligible subjects were randomly assigned, in a 2:1 ratio, to receive
once daily subcutaneous injections of liraglutide at a starting dose of 0.6 mg that was increased
in increments of 0.6 mg weekly over 4 weeks to the treatment dose.9 This trial used a modified
intent-to-treat analysis and subjects were selected based on inclusion/exclusion criteria noted in
Table 1 of which 423 were randomized to liraglutide and 212 to placebo; however, 324 subjects
in the liraglutide group and 140 subjects in the placebo group completed the 56 week trial.9 At
the conclusion of the trial, from a mean baseline body weight of 105.7 kg for liraglutide 3.0 mg
and 106.5 kg for placebo mean weight losses of 6.0% (6.4 kg) and 2.0% (2.2 kg) were seen.9 In
the liraglutide group, 25.2% of subjects lost more than 10% of their body weight compared to
6.7% of subjects in the placebo group (Table 2).9 Between groups, there was a statistically
significant difference, with p < 0.001 (Table 2).9 The estimated treatment difference was 18.5%
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[95% CI, 12.7% to 24.4%].9 This study was presented in dichotomous form and the relative
benefit increase was 2.761, the absolute benefit increase was 0.185, and the number needed to
treat was 6. Adverse events seen with liraglutide during this study included gastrointestinal
disorders.
The Sun et al. study compared liraglutide to placebo in adults with a BMI of 27-40 kg/m2
aged 40-70 years over a 14 week trial. Subjects were block-randomized by sex and BMI (<31
vs. 31 kg/m2) to receive a starting dose of liraglutide 0.6 mg once daily by subcutaneous
injection; the dose was titrated by 0.6 mg weekly to a maximum dose of 1.8 mg or placebo once
daily by subcutaneous injection.10 Sixty-nine individuals qualified for the study based on the
inclusion/exclusion criteria noted in Table 1 of which one withdrew from the study before
randomization.10 Eleven out of 35 individuals assigned to liraglutide discontinued participation
in the study compared with 6 out of 33 assigned to placebo (P = 0.26); 8 out of 11 individuals
using liraglutide discontinued participation due to adverse events compared with none assigned
to placebo (P = 0.009).10 Adverse events included intolerable gastrointestinal side effects (n = 3),
injection site reaction (n = 2), pneumonia (n = 1), gallstone (n = 1), and fall (n = 1).10 Thus, 24
subjects were randomized to the liraglutide group and 27 subjects assigned to the placebo group.
All subjects tolerated the 1.8 mg dose except two liraglutide subjects who required a dose
reduction down to 1.2 and 0.6 mg, respectively, and one placebo subject who required a dose
reduction down to 1.2 mg.10 At the end of the study it was evaluated that subjects randomized to
the liraglutide group lost twice as much weight as those assigned to the placebo group (6.8 vs 3.3
kg; P < 0.001).10 In the liraglutide group, 54% of subjects lost greater than or equal to 7% of
baseline body weight compared to 4% of subjects in the placebo group (Table 2.)10 Between the
groups, there was a statistically significant difference, with p < 0.001 (Table 2).10 The estimated
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treatment difference was -6.8 kg [95% CI, -7.8kg to -5.9kg].10 This study was presented in
dichotomous form and the relative benefit increase was 12.5, the absolute benefit increase was
0.5, and the number of patients who need to be treated to achieve one additional good outcome
was 2 (Table 3). This study found adverse effects from liraglutide related to the gastrointestinal
system.
The Pi-Sunyer et al. study focused on adults with a BMI of 30 kg/m2 or higher or 27
kg/m2 or higher if they had treated or untreated dyslipidemia or hypertension aged 18 years or
older over a 56 week trial. Eligible subjects were randomly assigned, in a 2:1 ratio, to receive
once daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg
increments to 3.0 mg, or placebo.11 A total of 3731 patients were selected based on the
inclusion/exclusion criteria noted in Table 1 of which 2487 were randomized to liraglutide and
1244 to placebo. In the liraglutide group, 246 of 2487 (9.9%) withdrew due to adverse events
compared to 47 of 1244 (3.8%) in the placebo group; 23 of 2487 (0.9%) in the liraglutide
withdrew due to ineffective therapy compared to 36 of 1244 (2.9%); other subjects withdrew
their consent.11 Thus, a total of 1789 patients (71.9%) in the liraglutide group, as compared with
801 patients (64.4%) in the placebo group, completed 56 weeks of treatment.11 At the end of the
study, subjects in the liraglutide group lost a mean of 8.0  6.7% (8.4  7.3 kg) of body weight
compared to 2.6  5.7% (2.8  6.5 kg) in the placebo group.11 In the liraglutide group, 33.1% of
subjects lost more than 10% of their body weight compared to 10.6% of subjects in the placebo
group (Table 2).11 Between groups, there was a statistically significant difference, with p < 0.001
(Table 2).11 The estimated treatment difference was -5.6 kg [95% CI, -6.0 to -5.1].11 This study
was also presented in dichotomous form and the relative benefit increase was 2.123, the absolute
benefit increase was 0.225, and the number needed to treat was 5. Adverse events were more
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commonly seen in subjects in the liraglutide group that consisted of gastrointestinal effects.
Table 2. Percentage of Bodyweight Lost and p-value by Study
Study
Liraglutide
Placebo

P-value

Davies et al.

25.2% lost >10% weight

6.7% lost >10% weight

<0.001

Sun et al.

54% lost 7% weight

4% lost 7% weight

<0.001

Pi-Sunyer et al.

33.1% lost >10% weight 10.6% lost >10% weight

Table 3. Calculations for Treatment by Study
Study
CER
EER
Davies et al.
0.067
0.252
Sun et al.
0.04
0.54
Pi-Sunyer et
0.106
0.331
al.

RBI
2.761
12.5
2.123

ABI
0.185
0.5
0.225

<0.001

NNT
6
2
5

DISCUSSION
Based on these three studies, liraglutide is effective at lowering body weight and is, in
fact, superior to placebo. Not only did liraglutide reduce bodyweight, it was effective in
improving insulin resistance, systolic blood pressure, glucose and triglyceride levels according to
the Sun et al. study. One flaw with this particular study, though, was the short duration of the
trial which only lasted 14 weeks. Another flaw of the Sun et al. study was the small sample size
along with 31% of subjects discontinuing participation from the liraglutide group. Pi-Sunyer et
al. found liraglutide to be effective in reducing bodyweight along with decreasing waist
circumference and inflammatory markers. The limitation with this study was the use of lastobservation-carried-forward imputation in the analyses.11 All three studies had limitations that,
most likely, affected the amount of weight lost by advising the subjects to exercise and diet. The
Sun et al. study instructed the subjects to eat a moderate carbohydrate diet with 43%
carbohydrate, 42% fat (< 7 saturated fat) and 15% protein and to decrease total caloric intake by
500 kcal/day.10 In the Pi-Sunyer et al. study both groups received counseling on lifestyle
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modification.11 In the Davies et al. study the subjects were encouraged to follow a diet
containing a maximum of 30% fat, 50% carbohydrate, with a 500 kcal/day reduction and an
exercise program that involved > 150 min/week of brisk walking.9
To continue, even though all three studies proved liraglutide to be effective at reducing
bodyweight, it comes with a host of adverse events, contraindications, and warnings on use.
Some of the contradictions of liraglutide include a personal or family history of medullary
thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, hypersensitivity to
liraglutide or any product components, and pregnancy.12 The FDA has listed the following
warnings with the use of liraglutide thyroid C-cell tumors, acute pancreatitis, acute gallbladder
disease, serious hypoglycemia which can occur with the concurrent use of sulfonylurea, heart
rate increase, renal impairment, hypersensitivity reactions, such as anaphylactic reactions and
angioedema, suicidal behavior and ideation.12 The FDA states the most common adverse
reactions, reported in greater than or equal to 5% are: nausea, hypoglycemia, diarrhea,
constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal
pain, and increased lipase, which has also been observed in all three of the studies.
CONCLUSION
The three studies in this review provide enough evidence to prove that liraglutide is
effective for weight loss in adults who are overweight or obese compared to placebo. Irrespective
of the dose used, it was shown that liraglutide reduced bodyweight from baseline. Due to the
adverse event profile of liraglutide, long term studies should assess the risk-benefit ratio, which
may lead to future studies assessing the effectiveness of low dose liraglutide on weight loss for
adults who have had adverse events from the higher dose. Also, future studies should include a
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broader age range to include children that are overweight or obese. Finally, future studies should
be conducted on subjects that are barred from exercise and diet to assess the full potential of
liraglutide and its effectiveness on weight reduction.
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